MIST Milestone Pharmaceuticals

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the , to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the , to be held April 7-9th in Berlin, Germany. The presentations will be available following the embargo at .

ACC Presentation Details:

 
Oral Presentation Title: Multi-Center, Open-Label Study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administered For Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision (Phase 3, NODE-303)
Presenter: James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
Date and time: Monday, April 8, 2024, 11:36 – 11:46 a.m. EDT
   
Poster Presentation Title: Symptom-prompted, Self-administered Intranasal Etripamil for Termination of Paroxysmal Supraventricular Tachycardia in the RAPID Study: Relationship Among Etripamil-Induced Reduction in Tachycardia Rates, Conversion to Sinus Rhythm, and Improvement in Patient Symptoms
Presenter: James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
Date and time: Sunday, April 7, 2024, 12:15 – 1:00 p.m. EDT
   
EHRA Presentation Details:
   
Poster Presentation Title: Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes
Presenter: David Bharucha, M.D., Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals, Inc.
Date and time: Sunday, April 7, 2024, 10:15 a.m. CET
   

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat highly symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:

Kim Fox, Vice President, Communications

Investor Relations

Chris Calabrese,  

Kevin Gardner,

 



EN
01/04/2024

Underlying

MISTMilestone Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Milestone Pharmaceuticals

 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Result...

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Offering Raised Total Gross Proceeds of up to $170 Million if all Warrants are Exercised $75 Million Royalty Purchase Agreement Payment from RTW Extended Through End of 2025 MONTREAL and CHARLOTTE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Milestone Pharma...

August 12, 2025 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Of...

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A com...

July 11, 2025 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces Proposed Public Offering MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares, accompanying Series A warrants to purchase common shares (the “Series A Warrants”) and accompanying Series B warrants to purchase common shares (the “Series B Warrants”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, accompa...

July 11, 2025 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Re...

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigationa...

July 11, 2025 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAM...

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in a...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch